7.85 USD
-0.11 (-1.38%)
7.75 USD
-0.1 (-1.27%)
We assign a fundamental rating of 2 out of 10 to PSNL. PSNL was compared to 57 industry peers in the Life Sciences Tools & Services industry. While PSNL seems to be doing ok healthwise, there are quite some concerns on its profitability. PSNL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PSNL had negative earnings in the past year.
In the past year PSNL has reported a negative cash flow from operations.
PSNL had negative earnings in each of the past 5 years.
PSNL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -30.42%, PSNL is not doing good in the industry: 75.44% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -43.10%, PSNL is doing worse than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.42% | ||
| ROE | -43.1% | ||
| ROIC | N/A |
ROA(3y)-38.97%
ROA(5y)-30.04%
ROE(3y)-58.56%
ROE(5y)-43.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PSNL has a worse Gross Margin (26.67%) than 78.95% of its industry peers.
In the last couple of years the Gross Margin of PSNL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for PSNL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.05%
GM growth 5Y-1.31%
2. Health
2.1 Basic Checks
PSNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSNL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PSNL has been increased compared to 5 years ago.
Compared to 1 year ago, PSNL has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.30 indicates that PSNL is not a great score, but indicates only limited risk for bankruptcy at the moment.
PSNL has a Altman-Z score (2.30) which is comparable to the rest of the industry.
PSNL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PSNL has a better Debt to Equity ratio (0.00) than 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.3 |
ROIC/WACCN/A
WACC10.84%
2.3 Liquidity
PSNL has a Current Ratio of 4.82. This indicates that PSNL is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.82, PSNL is doing good in the industry, outperforming 77.19% of the companies in the same industry.
A Quick Ratio of 4.69 indicates that PSNL has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 4.69, PSNL belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.82 | ||
| Quick Ratio | 4.69 |
3. Growth
3.1 Past
PSNL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 47.62%, which is quite impressive.
PSNL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.02%.
The Revenue has been growing slightly by 5.35% on average over the past years.
EPS 1Y (TTM)47.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
Revenue 1Y (TTM)-21.02%
Revenue growth 3Y-0.34%
Revenue growth 5Y5.35%
Sales Q2Q%-43.62%
3.2 Future
The Earnings Per Share is expected to grow by 14.35% on average over the next years. This is quite good.
PSNL is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.60% yearly.
EPS Next Y29.7%
EPS Next 2Y13.04%
EPS Next 3Y12.23%
EPS Next 5Y14.35%
Revenue Next Year-16.36%
Revenue Next 2Y0.32%
Revenue Next 3Y8.68%
Revenue Next 5Y14.6%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
PSNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PSNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PSNL's earnings are expected to grow with 12.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.04%
EPS Next 3Y12.23%
5. Dividend
5.1 Amount
No dividends for PSNL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.85
-0.11 (-1.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners54.27%
Inst Owner Change4.67%
Ins Owners1.14%
Ins Owner Change-0.22%
Market Cap697.08M
Revenue(TTM)69.10M
Net Income(TTM)-73.88M
Analysts83.08
Price Target11.22 (42.93%)
Short Float %14.07%
Short Ratio5.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)7.49%
Max EPS beat(2)15.55%
EPS beat(4)4
Avg EPS beat(4)18.13%
Min EPS beat(4)7.49%
Max EPS beat(4)28.59%
EPS beat(8)6
Avg EPS beat(8)7.71%
EPS beat(12)8
Avg EPS beat(12)6.28%
EPS beat(16)11
Avg EPS beat(16)6.11%
Revenue beat(2)1
Avg Revenue beat(2)-4.68%
Min Revenue beat(2)-16.15%
Max Revenue beat(2)6.79%
Revenue beat(4)3
Avg Revenue beat(4)2.82%
Min Revenue beat(4)-16.15%
Max Revenue beat(4)15.99%
Revenue beat(8)6
Avg Revenue beat(8)5.8%
Revenue beat(12)9
Avg Revenue beat(12)5.37%
Revenue beat(16)12
Avg Revenue beat(16)5.55%
PT rev (1m)3.53%
PT rev (3m)55.75%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.05%
EPS NY rev (1m)2.08%
EPS NY rev (3m)2.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.69%
Revenue NY rev (1m)-4.45%
Revenue NY rev (3m)-4.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 10.09 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.07 | ||
| P/tB | 4.07 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.88
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-0.75
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0.78
BVpS1.93
TBVpS1.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.42% | ||
| ROE | -43.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 26.67% | ||
| FCFM | N/A |
ROA(3y)-38.97%
ROA(5y)-30.04%
ROE(3y)-58.56%
ROE(5y)-43.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.05%
GM growth 5Y-1.31%
F-Score3
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 56.02% | ||
| Cap/Sales | 8.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.82 | ||
| Quick Ratio | 4.69 | ||
| Altman-Z | 2.3 |
F-Score3
WACC10.84%
ROIC/WACCN/A
Cap/Depr(3y)234.39%
Cap/Depr(5y)188.79%
Cap/Sales(3y)31.15%
Cap/Sales(5y)22.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%62.5%
EPS Next Y29.7%
EPS Next 2Y13.04%
EPS Next 3Y12.23%
EPS Next 5Y14.35%
Revenue 1Y (TTM)-21.02%
Revenue growth 3Y-0.34%
Revenue growth 5Y5.35%
Sales Q2Q%-43.62%
Revenue Next Year-16.36%
Revenue Next 2Y0.32%
Revenue Next 3Y8.68%
Revenue Next 5Y14.6%
EBIT growth 1Y-15.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.31%
EBIT Next 3Y-0.78%
EBIT Next 5Y15.71%
FCF growth 1Y13.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.5%
OCF growth 3YN/A
OCF growth 5YN/A
PERSONALIS INC / PSNL FAQ
Can you provide the ChartMill fundamental rating for PERSONALIS INC?
ChartMill assigns a fundamental rating of 2 / 10 to PSNL.
Can you provide the valuation status for PERSONALIS INC?
ChartMill assigns a valuation rating of 0 / 10 to PERSONALIS INC (PSNL). This can be considered as Overvalued.
What is the profitability of PSNL stock?
PERSONALIS INC (PSNL) has a profitability rating of 0 / 10.
What is the financial health of PERSONALIS INC (PSNL) stock?
The financial health rating of PERSONALIS INC (PSNL) is 5 / 10.